UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 4,784 Shares of Glaukos Corporation $GKOS

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in Glaukos Corporation (NYSE:GKOS) by 3.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 138,990 shares of the medical instruments supplier’s stock after selling 4,784 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.24% of Glaukos worth $19,425,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of GKOS. AQR Capital Management LLC lifted its position in shares of Glaukos by 2.6% during the 1st quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock worth $766,000 after buying an additional 198 shares during the last quarter. Jones Financial Companies Lllp grew its position in Glaukos by 1,405.9% in the first quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock valued at $252,000 after acquiring an additional 2,390 shares during the last quarter. M&T Bank Corp bought a new position in Glaukos in the second quarter valued at about $203,000. Gamco Investors INC. ET AL raised its stake in Glaukos by 10.7% during the second quarter. Gamco Investors INC. ET AL now owns 8,001 shares of the medical instruments supplier’s stock worth $826,000 after acquiring an additional 773 shares in the last quarter. Finally, State Street Corp raised its stake in Glaukos by 5.3% during the second quarter. State Street Corp now owns 2,090,365 shares of the medical instruments supplier’s stock worth $215,914,000 after acquiring an additional 105,972 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Insider Buying and Selling at Glaukos

In other Glaukos news, COO Joseph Gilliam sold 60,000 shares of Glaukos stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the transaction, the chief operating officer directly owned 72,588 shares of the company’s stock, valued at approximately $13,046,967.12. The trade was a 45.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Leana Wen sold 525 shares of the company’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $167.63, for a total value of $88,005.75. Following the completion of the sale, the director owned 21,092 shares in the company, valued at $3,535,651.96. This trade represents a 2.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 113,025 shares of company stock worth $19,600,006. Company insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on GKOS. Wells Fargo & Company raised their price target on shares of Glaukos from $138.00 to $178.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research note on Friday, July 17th. Piper Sandler restated an “overweight” rating and issued a $195.00 target price (up from $165.00) on shares of Glaukos in a research report on Thursday, July 30th. Stifel Nicolaus boosted their target price on shares of Glaukos from $175.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Finally, Citigroup upped their price target on shares of Glaukos from $175.00 to $188.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Glaukos presently has a consensus rating of “Moderate Buy” and an average price target of $178.08.

Glaukos Stock Down 1.2%

NYSE:GKOS opened at $178.20 on Friday. The firm’s 50 day simple moving average is $166.72 and its 200 day simple moving average is $136.35. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. Glaukos Corporation has a one year low of $73.16 and a one year high of $191.62. The company has a market cap of $10.51 billion, a PE ratio of -54.83 and a beta of 0.76.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. The firm had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The company’s revenue for the quarter was up 49.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.24) EPS. On average, research analysts anticipate that Glaukos Corporation will post -0.32 earnings per share for the current year.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.